Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension study of ABT-494 for Crohn's disease
MOH_2017-03-05_000110Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of upadacitinib in Crohn's disease (2 arms), sponsored by AbbVie Inc. Started Nov 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-03-05_000110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-05_000110.